Menu

Rich represents high growth companies, investment banks and institutional investors in equity and debt offerings, with a focus on the technology and life sciences sectors. Rich also regularly counsels public companies on SEC compliance and reporting matters, as well as private companies on a wide variety of corporate and securities matters.

Download full bio 

Experience

  • Karuna Therapeutics – $862.5 Million Follow-on Offering 

  • Verve Therapeutics – $258.8 Million Follow-on Offering 

  • Verve Therapeutics – $258.8 Million Follow-on Offering 

  • EyePoint Pharmaceuticals – $115.4 Million Follow-on Offering 

  • Zentalis Pharmaceuticals – $200 Million Follow-On Offering 

  • View all

Education

  • Boston College Law School
    JD, cum laude, 2009

  • Dartmouth College
    AB, cum laude, 2005


Admissions & Credentials

Admitted to practice in Massachusetts only

Not admitted to practice in New York

Rankings & Accolades

    Legal 500: Next Generation Partner – Capital Markets: Equity Offerings (2021 – 2022)

    Massachusetts Super Lawyers: Rising Star – Securities & Corporate Finance (2013 – 2021)

    Chambers USA: Capital Markets – Massachusetts